These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 19920924)
21. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin. Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176 [TBL] [Abstract][Full Text] [Related]
22. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition. Gao M; Xu Y; Qiu L J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110 [TBL] [Abstract][Full Text] [Related]
23. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction. Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453 [TBL] [Abstract][Full Text] [Related]
24. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells. Wang TX; Yang XH Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331 [TBL] [Abstract][Full Text] [Related]
25. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin. Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008 [TBL] [Abstract][Full Text] [Related]
26. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Xu HB; Li L; Liu GQ Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169 [TBL] [Abstract][Full Text] [Related]
27. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells. Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559 [TBL] [Abstract][Full Text] [Related]
28. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697 [TBL] [Abstract][Full Text] [Related]
29. A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells. Prasad P; Cheng J; Shuhendler A; Rauth AM; Wu XY Drug Deliv Transl Res; 2012 Apr; 2(2):95-105. PubMed ID: 25786718 [TBL] [Abstract][Full Text] [Related]
30. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway. Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650 [TBL] [Abstract][Full Text] [Related]
31. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line. Li J; Xu LZ; He KL; Guo WJ; Zheng YH; Xia P; Chen Y Breast Cancer Res; 2001; 3(4):253-63. PubMed ID: 11434876 [TBL] [Abstract][Full Text] [Related]
32. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Ji BS; He L; Liu GQ Life Sci; 2005 Sep; 77(18):2221-32. PubMed ID: 15967469 [TBL] [Abstract][Full Text] [Related]
33. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate. Leontieva OV; Preobrazhenskaya MN; Bernacki RJ Invest New Drugs; 2002 Feb; 20(1):35-48. PubMed ID: 12003193 [TBL] [Abstract][Full Text] [Related]
34. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. Thierry AR; Vigé D; Coughlin SS; Belli JA; Dritschilo A; Rahman A FASEB J; 1993 Apr; 7(6):572-9. PubMed ID: 8097173 [TBL] [Abstract][Full Text] [Related]
35. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells. Jiang J; Wang X; Cheng K; Zhao W; Hua Y; Xu C; Yang Z Mol Med Rep; 2016 Jun; 13(6):4745-50. PubMed ID: 27082231 [TBL] [Abstract][Full Text] [Related]
36. ATP-dependent activity and mitochondrial localization of drug efflux pumps in doxorubicin-resistant breast cancer cells. Dartier J; Lemaitre E; Chourpa I; Goupille C; Servais S; Chevalier S; Mahéo K; Dumas JF Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):1075-1084. PubMed ID: 28214549 [TBL] [Abstract][Full Text] [Related]
37. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells. Abdin SM; Tolba MF; Zaher DM; Omar HA Chem Biol Interact; 2021 May; 340():109450. PubMed ID: 33775688 [TBL] [Abstract][Full Text] [Related]
38. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines. Grandjean F; Brémaud L; Verdier M; Robert J; Ratinaud MH Anticancer Drugs; 2001 Mar; 12(3):247-58. PubMed ID: 11290872 [TBL] [Abstract][Full Text] [Related]
39. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model. Tiash S; Chowdhury EH J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549 [TBL] [Abstract][Full Text] [Related]
40. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR). Krishna R; Mayer LD Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]